Dr. Goodman is also involved in collaborative efforts with the San Antonio Bone Marrow Transplant Center to study the outcome
of allogeneic bone marrow transplants following a relapse from autologous bone marrow transplants.
Not exact matches
Collaboration with Hematology and
Bone Marrow Transplantation Unit research group in molecular diagnostics applied to the management
of patients undergoing
allogeneic SCT, especially for the detection
of minimal residual disease and early relapse.
In close collaboration with universities and physicians world - wide, our comprehensive investigational stem cell treatments employ well - targeted combinations
of allogeneic human umbilical cord stem cells, autologous
bone marrow stem cells, and autologous adipose stem cells for the diseases listed below.
Board - certified in internal medicine and medical oncology, Dr. Collins has 25 years
of experience in
bone marrow transplantation and has participated in some 2,500 autologous and
allogeneic transplants.
Reconstitution with syngeneic plus
allogeneic or xenogeneic
bone marrow leads to specific acceptance
of allografts or xenografts.
In the future, outpatient blood and
bone marrow stem cell transplantation will be offered to a broader group
of patients with other blood disorders and for
allogeneic transplants (transplant from non-twin donor stem cells).
Allogeneic stem cell transplantation to leukaemic patients, in which the patient's own diseased
bone marrow is replaced by healthy donor material, is one
of the best - established and most effective immunological therapies.
Allogeneic cell therapies involving primary cell types such as
bone marrow mesenchymal stromal / stem cells (BM - MSCs), hematopoietic stem and progenitor cells (HSPCs), and T and natural killer (NK) cells for immunotherapy applications are especially challenging because
of the vigorous process
of screening...
Patients receive one
of two types
of stem cell - based transplants: autologous, in which a patient donates and receives back his / her own stem cells; or
allogeneic, in which
bone marrow - derived stem cells come from a related or unrelated donor whose human leukocyte antigens (HLA) are genetically matched with those
of a patient.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML: The results
of a new study that included patients from the PACE trial and the European
Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with
allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.